Erythropoietin Stimulating Agents (ESA)

November 27th, 2017 - Wyn Staheli, Director of Research
Categories:   Documentation Guidelines   Billing   Modifiers  
0 Votes - Sign in to vote or comment.

Coverage

ESA is typically covered for the following condition(s):

It could also be covered as preoperative treatment for patients undergoing a surgery (e.g., knee or hip replacement) when both the following are met:

  • patient is expected to lose more than 2 units of blood
  • patient has anemia and is not a good candidate for transfusions

Documentation

Before beginning ESA therapy, be sure to document (where applicable) any underlying causes of anemia which have been considered, and corrected where possible, such as:

  • Underlying infection or inflammatory process
  • Underlying hematological disease
  • Hemolysis
  • Vitamin deficiencies (e.g. folic acid or B12)
  • Blood loss
  • Aluminum intoxication

Comprehensive assessment which includes the following:

  • Hematocrit or hemoglobin
  • Serum iron
  • Transferrin saturation; or serum ferritin and /or documentation of iron stores in bone marrow
    Creatinine
  • Bone Marrow Biopsy (for myelodysplastic disease or where otherwise indicated)
  • Erythropoietin level (for myelodysplastic disease; AZT therapy, anemia of chronic disease)

Commonly Associated Modifiers: AYEA , EBECEDEEGSJAJB

Billing Note

Medicare will generally only covers ESRD-related drugs and biologicals when be billed by the renal dialysis facility. However, if an ESRD-related drug or biological was furnished to an ESRD beneficiary for reasons other than for the treatment of ESRD, it may be billed separately using modifier AY.

ESRD-related EPO is included in ESRD payment system and thus are not separately payable via Part B claims, however, there can be an exception for hospital billing when there is an emergency or unscheduled dialysis session.

Payer Guidelines

Be sure to verify coverage and review treatment policies with individual commercial payers or your Medicare Administrative Contractor (MAC) before beginning treatment. To review your MAC-specific carrier LCD, check the [Medicare Policies & Guidelines] portion shown below the code.

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

​​Polysomnography Services Under OIG Scrutiny
September 2nd, 2021 - Raquel Shumway
The OIG conducted a study dated June 2019 wherein they indicated that there were approximately $269 million in overpayments for polysomnography services for the period of 2014 through 2015. According to the OIG “These errors occurred because the CMS oversight of polysomnography services was insufficient to ensure that providers complied with Medicare requirements and to prevent payment of claims that didn’t meet those requirements.” So what are those requirements?
Medicare Advantage - The Fastest Growing Government-Funded Program Undergoing Multiple Fraud Investigations
August 16th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Medicare Advantage is the fastest growing form of government-funded healthcare and the rate of fraud within this segment has come under increased scrutiny. Funding is determined by the health status of each beneficiary; therefore, accurate coding based on detailed documentation makes the medical record vital to the process because some ...
Billing Dental Implants under Medical Coverage
August 12th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
Implants can be costly to the patient and the provider, and it is crucial to understand how to bill a patient’s medical insurance to ensure there is adequate coverage for the best treatment. Implants are commonly billed in a dental office under a patient’s medical benefits.    Implants could be considered ...
New Codes for COVID Booster Vaccine & Monoclonal Antibody Products
August 10th, 2021 - Wyn Staheli, Director of Research
New codes have been announced for the COVID-19 booster vaccine, Novavax vaccine, and monoclonal antibody treatment.
Medicare's ABN Booklet Revised
July 29th, 2021 - Wyn Staheli, Director of Research
The “Medicare Advance Written Notices of Non-coverage” booklet, published by CMS’s Medicare Learning Network, was updated. This article discusses the changes to this booklet regarding the use of the ABN.
Chronic Pain Coding Today & in the Future
July 19th, 2021 - Wyn Staheli, Director of Research
Properly documenting and coding chronic pain can be challenging. As is commonly the case with many conditions, over the years, there has been a shift in the identification of different types of pain, including chronic pain. Understanding where we are now and where we are going will help your organization prepare for the future by changing documentation patterns now.
How Does Global and Professional Direct Contracting (GPDC) Affect Risk Adjustment?
July 15th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
CMS recently announced the 53 Direct Contracting Entities (DCEs) that will be participating in the April 1, 2021 through December 31, 2021 Global and Professional Direct Contracting (GPDC) Model. Among those participating is Clover Health Partners, who runs an in-home primary care program that has the potential to help Medicare ...



Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association